Nasdaq

Lipella Pharmaceuticals Reports Positive Phase 2a Results for LP-310 Oral Rinse in Treating Oral Lichen Planus

LP-310 shows significant improvements in pain and inflammation for oral lichen planus, with favorable safety results in Phase 2a trial. Lipella Pharmaceuticals has announced promising results from its ...
Medscape

Zerlasiran siRNA Drug Lowers Lp(a) by 90% in Phase 2 Results

Silence Therapeutics announced positive topline 36-week data from its ongoing phase 2 study of zerlasiran, a long-acting agent directed at lowering Lp(a) levels. In a statement, the company said the ...
Seeking Alpha

Lipella Pharmaceuticals Completes Enrollment in Phase 2a Trial of LP-310 for Oral Lichen Planus

PITTSBURGH, April 08, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company focused on developing innovative therapies for ...
Seeking Alpha

Lipella Pharmaceuticals Announces Completion of First Cohort in Phase 2a Trial of LP-310 for Oral Lichen Planus, Advancing to Next Dose Group

PITTSBURGH, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company focused on innovative therapies for serious ...
Morningstar

Superior Efficacy and Long-acting: LongBio Announces Positive Topline Results from Phase II CSU Trial of Next-Generation Anti-IgE Therapy, LP-003 in Head-to-Head Comparison ...

PHILADELPHIA, March 2, 2026 /PRNewswire/ -- LongBio Pharma (Suzhou) Co., Ltd. ("LongBio"), a clinical-stage biotech company focused on discovery and development of biologics targeting allergic and ...
Nasdaq

Lipella Pharmaceuticals Inc. Reports Positive Topline Results from Phase 2a Trial of LP-310 for Oral Lichen Planus

Lipella Pharmaceuticals Inc. announced positive topline results from the second cohort of its Phase 2a clinical study of LP-310, a liposomal-tacrolimus oral rinse aimed at treating oral lichen planus ...